Concomitant ixekizumab and tirzepatide significantly improved skin clearance and weight reduction in adults with moderate to severe plaque psoriasis.

Skye Bioscience reports Phase 2a data showing nimacimab plus semaglutide led to over 22% weight loss at 52 weeks, with lower weight regain and no serious safety issues.

The advent of GLP-1 receptor agonists has revolutionized the approach to obesity treatment. These weight management drugs, which mimic natural hormones that regulate insulin and glucose levels, have ...

New findings indicate that in adults with moderate-to-severe plaque psoriasis who are overweight or obese, combined treatment with ixekizumab (Taltz) and tirzepatide (Zepbound) results ...

ORLANDO -- Postmenopausal women using hormone therapy (HT) saw significantly greater weight loss while taking the dual GIP/GLP-1 receptor agonist tirzepatide than their counterparts not using HT, ...

Skye Bioscience has published 52-week data on its investigational obesity drug combination, linking the cocktail to 22.3% total weight loss as it works to recover from its failure to hit the primary ...

Combining hormonal therapy and tirzepatide may lead to the greatest weight loss after menopause, new evidence suggests.

An experimental combo drug from Novo Nordisk leads to more weight loss than semaglutide alone, according to late-stage trial data.

A revolutionary study has suggested that the glycemic content of foods may be the key to weight loss. A revolutionary study has suggested that the glycemic content of foods may be the key to weight ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with or without type 2 diabetes, a pair of phase IIIa trials found. This ...

Excess body weight may help explain why some chronic illnesses frequently occur together, according to a study.